Related Experiment Video

Updated: Apr 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Does pharmacotherapy improve cardiovascular outcomes in hemodialysis patients?

Mayank Mittal1, Kul Aggarwal1, Rachel L Littrell1

  • 1Division of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA.

Hemodialysis International. International Symposium on Home Hemodialysis
|October 9, 2015
PubMed

Insights

Cardiovascular disease (CVD) is common in chronic kidney disease (CKD) patients on hemodialysis (HD). Pharmacotherapy for CVD is generally less effective in HD patients compared to the general population.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Pharmacology

Background:

  • Cardiovascular disease (CVD) is highly prevalent in patients with chronic kidney disease (CKD), particularly those undergoing hemodialysis (HD).
  • Established pharmacologic treatments for hypertension, dyslipidemia, coronary artery disease, and atrial fibrillation are effective in the general population.
  • Outcomes data for pharmacotherapy in CKD and HD patients are limited compared to the general population.

Purpose of the Study:

  • To evaluate the effectiveness of pharmacotherapy for common cardiovascular conditions in patients with CKD, especially those on HD.
  • To compare the efficacy of CVD pharmacotherapies in HD patients versus the general population or early-stage CKD patients.

Main Methods:

  • Review of available data and clinical trials concerning pharmacotherapy for cardiovascular conditions in CKD and HD patients.
  • Comparative analysis of treatment efficacy across different patient populations (general, early CKD, HD).

Main Results:

  • Pharmacotherapy for hypertension and dyslipidemia shows reduced effectiveness in HD patients.
  • Anti-platelet therapy for CVD and anticoagulant therapy for atrial fibrillation are also less effective in HD patients.
  • Overall, pharmacologic interventions for cardiovascular conditions yield poorer outcomes in HD patients compared to other populations.

Conclusions:

  • Standard pharmacologic management of cardiovascular diseases is less effective in hemodialysis patients.
  • Further research is needed to optimize cardiovascular pharmacotherapy for the CKD and HD population.
  • Clinical outcomes for CVD pharmacotherapy are significantly poorer in HD patients than in the general population.

Keywords:
Cardiovascular diseaseanti-platelet therapyanticoagulationdyslipidemiahemodialysishypertension

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

9.0K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.5K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
532
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
580
Hemodialysis III: Nursing Management01:25

Hemodialysis III: Nursing Management

The nursing management of a patient undergoing hemodialysis includes several critical steps, starting with a thorough assessment before the procedure.Before the Hemodialysis ProcedureFirst, record the patient's vital signs—blood pressure, heart rate, respiratory rate, and temperature—to establish a baseline. This baseline is essential for detecting conditions such as hypotension that could impact the patient's response to dialysis. Document the patient's pre-dialysis weight, as this...
1.5K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
641